Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | FASN | P49327 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4339845 | 1.00 | CYP1A2 (0.51) | CYP1A2PPARGALDH1A1GRM2SIRT2 | |
| SCHEMBL8394045 | 1.00 | CYP1A2 (0.51) | CYP1A2PPARGALDH1A1GRM2SIRT2 | |
| SCHEMBL18979113 | 1.00 | CYP1A2 (0.51) | CYP1A2PPARGALDH1A1GRM2SIRT2 | |
| SCHEMBL18981127 | 1.00 | CYP1A2 (0.51) | CYP1A2PPARGALDH1A1GRM2SIRT2 | |
| SCHEMBL7153568 | 0.98 | CYP1A2 (0.49) | CYP1A2PPARGALDH1A1GRM2SIRT2 | |
| SCHEMBL8394086 | 0.93 | CYP1A2 (0.42) | CYP1A2PPARGGRM2SIRT2POLB | |
| SCHEMBL8396285 | 0.85 | KAT2A (0.39) | CYP1A2SIRT2POLBFASNPTPN1 | |
| SCHEMBL19729125 | 0.83 | CYP1A2 (0.33) | CYP1A2PPARGGRM2SIRT2POLB | |
| SCHEMBL7024404 | 0.81 | CYP1A2 (0.67) | CYP1A2PPARGALDH1A1GRM2SIRT2 | |
| SCHEMBL20803560 | 0.81 | CYP1A2 (0.67) | CYP1A2PPARGALDH1A1GRM2SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359277-B2 | Compositions and processes of preparing and using the same | PURDUE RESEARCH FOUNDATION (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359277-B2 | Compositions and processes of preparing and using the same | PURDUE RESEARCH FOUNDATION (US) | 2016-06-07 | — | — | US | disclosed |
| US-20140039182-A1 | COMPOSITIONS AND PROCESSES OF PREPARING AND USING THE SAME | PURDUE RESEARCH FOUNDATION | 2014-02-06 | — | — | US | disclosed |
| US-20140039182-A1 | COMPOSITIONS AND PROCESSES OF PREPARING AND USING THE SAME | PURDUE RESEARCH FOUNDATION | 2014-02-06 | — | — | US | disclosed |
| WO-2012129384-A2 | COMPOSITIONS AND PROCESSES OF PREPARING AND USING THE SAME | PURDUE RESEARCH FOUNDATION (US) | 2012-09-27 | — | — | WO | disclosed |
| WO-2012129384-A2 | COMPOSITIONS AND PROCESSES OF PREPARING AND USING THE SAME | PURDUE RESEARCH FOUNDATION (US) | 2012-09-27 | — | — | WO | disclosed |
| US-8093409-B2 | Method for producing cyclic unsaturated compound | NIPPON SHOKUBAI CO., LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| US-20090299009-A1 | METHOD FOR PRODUCING CYCLIC UNSATURATED COMPOUND | NIPPON SHOKUBAI CO., LTD. (JP) | 2009-12-03 | — | — | US | disclosed |
| WO-2008023823-A1 | METHOD FOR PRODUCING CYCLIC UNSATURATED COMPOUND | NIPPON SHOKUBAI CO., LTD. (JP) | 2008-02-28 | — | — | WO | disclosed |
| EP-0722960-B1 | Copolymers for preparing cast glass, or molding materials for preparing heat stable shaped articles | AGOMER GES MIT BESCHRAENKTER H (DE) | 1999-06-02 | — | — | EP | disclosed |
| US-5880235-A | POLYMER PREPARED BY COPOLYMERIZING ALPHA-METHYLENE-GAMMA-BUTYROLACTONE AND VINYLICALLY UNSATURATED MONOMER | AGOMER GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1999-03-09 | — | — | US | disclosed |
| EP-0722960-A2 | Copolymers for preparing cast glass, or molding materials for preparing heat stable shaped articles | Degussa Aktiengesellschaft (DE) | 1996-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140039182-A1 | COMPOSITIONS AND PROCESSES OF PREPARING AND USING THE SAME | DBF4, FAU, DHX29 | CYP1A2 3750/4885PPARG 3135/4885ALDH1A1 2102/4885 |
| US-20090299009-A1 | METHOD FOR PRODUCING CYCLIC UNSATURATED COMPOUND | FASN, SQLE, ALOX5 | CYP1A2 191/4885PPARG 158/4885ALDH1A1 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.